There have even been reports of MS onset in TNF-α-blocker therapy for treatment of other diseases (Titelbaum et al., 2005; Al Saieg and Luzar, 2006; Pfueller et al., 2008; Bradshaw et al., 2016), pointing to the sensitivity of MS to levels of systemic TNF-α. Here, TNF is linked to myeloid sarcoma.